CNS Pharmaceuticals, Inc. Earnings Per Share, Basic and Diluted
CNS Pharmaceuticals, Inc. (CNSP) reported Earnings Per Share, Basic and Diluted of -$0.53 per share for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-03.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2022-03-03
- CNS Pharmaceuticals, Inc. earnings per share, basic and diluted for the quarter ending 2021-12-31 was -$0.12.
- CNS Pharmaceuticals, Inc. earnings per share, basic and diluted for the quarter ending 2021-09-30 was -$0.14.
- CNS Pharmaceuticals, Inc. earnings per share, basic and diluted for the quarter ending 2021-06-30 was -$0.15.
- CNS Pharmaceuticals, Inc. earnings per share, basic and diluted for the quarter ending 2021-03-31 was -$0.15.
- CNS Pharmaceuticals, Inc. earnings per share, basic and diluted for fiscal 2021 was -$0.53.
- CNS Pharmaceuticals, Inc. earnings per share, basic and diluted for fiscal 2020 was -$0.57.
- CNS Pharmaceuticals, Inc. earnings per share, basic and diluted for fiscal 2019 was -$0.28.
- CNS Pharmaceuticals, Inc. earnings per share, basic and diluted for fiscal 2018 was -$0.70.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2021-12-31 | -$0.12 derived: net income ÷ weighted average shares · filed 2023-03-31 | -$0.26 derived: net income ÷ weighted average shares · filed 2023-03-31 | -$0.40 derived: net income ÷ weighted average shares · filed 2023-03-31 | -$0.53 10-K · filed 2022-03-03 |
| 2021-09-30 | -$0.14 10-Q · filed 2021-11-12 | -$0.29 derived: net income ÷ weighted average shares · filed 2022-11-10 | -$0.43 10-Q · filed 2021-11-12 | -$0.60 derived: net income ÷ weighted average shares · filed 2022-11-10 |
| 2021-06-30 | -$0.15 10-Q · filed 2021-08-13 | -$0.30 10-Q · filed 2021-08-13 | -$0.47 derived: net income ÷ weighted average shares · filed 2022-11-10 | -$0.59 derived: net income ÷ weighted average shares · filed 2022-11-10 |
| 2021-03-31 | -$0.15 10-Q · filed 2021-05-13 | -$0.32 derived: net income ÷ weighted average shares · filed 2022-11-10 | -$0.44 derived: net income ÷ weighted average shares · filed 2022-11-10 | -$0.59 derived: net income ÷ weighted average shares · filed 2022-11-10 |
| 2020-12-31 | -$0.18 derived: net income ÷ weighted average shares · filed 2022-03-03 | -$0.30 derived: net income ÷ weighted average shares · filed 2022-03-03 | -$0.45 derived: net income ÷ weighted average shares · filed 2022-03-03 | -$0.57 10-K · filed 2022-03-03 |
| 2020-09-30 | -$0.12 10-Q · filed 2021-11-12 | -$0.27 derived: net income ÷ weighted average shares · filed 2021-11-12 | -$0.39 10-Q · filed 2021-11-12 | -$0.56 derived: net income ÷ weighted average shares · filed 2021-11-12 |
| 2020-06-30 | -$0.15 10-Q · filed 2021-08-13 | -$0.27 10-Q · filed 2021-08-13 | -$0.44 derived: net income ÷ weighted average shares · filed 2021-08-13 | -$0.50 derived: net income ÷ weighted average shares · filed 2021-08-13 |
| 2020-03-31 | -$0.12 10-Q · filed 2021-05-13 | -$0.29 derived: net income ÷ weighted average shares · filed 2021-05-13 | -$0.35 derived: net income ÷ weighted average shares · filed 2021-05-13 | -$0.39 derived: net income ÷ weighted average shares · filed 2021-05-13 |
| 2019-12-31 | -$0.17 derived: net income ÷ weighted average shares · filed 2021-02-12 | -$0.23 derived: net income ÷ weighted average shares · filed 2021-02-12 | -$0.26 derived: net income ÷ weighted average shares · filed 2021-02-12 | -$0.28 10-K · filed 2021-02-12 |
| 2019-09-30 | -$0.05 10-Q · filed 2020-11-12 | -$0.09 derived: net income ÷ weighted average shares · filed 2020-11-12 | -$0.10 10-Q · filed 2020-11-12 | -$0.64 derived: net income ÷ weighted average shares · filed 2020-11-12 |
| 2019-06-30 | -$0.03 10-Q · filed 2020-08-10 | -$0.05 10-Q · filed 2020-08-10 | -$0.60 derived: net income ÷ weighted average shares · filed 2020-11-12 | -$0.64 derived: net income ÷ weighted average shares · filed 2020-11-12 |
| 2019-03-31 | -$0.02 10-Q · filed 2020-05-15 | -$0.59 derived: net income ÷ weighted average shares · filed 2020-11-12 | -$0.63 derived: net income ÷ weighted average shares · filed 2020-11-12 | |
| 2018-12-31 | -$0.63 derived: net income ÷ weighted average shares · filed 2020-03-12 | -$0.65 derived: net income ÷ weighted average shares · filed 2020-03-12 | -$0.70 10-K · filed 2020-03-12 | |
| 2018-09-30 | -$0.02 10-Q · filed 2019-12-20 | -$0.07 10-Q · filed 2019-12-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |